We could recapitulate the CA flow reduction trend from WT to Marcksl1 KO networks (observed in experiments) in CFD models under two BC scenarios for the mutant models–BCs prescribing arterial pressure maintenance (from WT) in model ML1KO1 and BCs prescribing arterial pressure reduction in model ML1KO2 (Fig 7C, 7E and 7F). The gene discussed is MARCKSL1; the disease is breast cancer.